Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Research interests include Medicine, Internal medicine, Apatinib, Lung cancer, Oncology, and Adverse effect.
Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
PL04.13 Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: Interim Results of the Phase III Study (POLESTAR)
196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
International consensus on radiotherapy in metastatic non-small cell lung cancer
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Efficient dose–volume histogram–based pretreatment patient‐specific quality assurance methodology with combined deep learning and machine learning models for volumetric modulated arc radiotherapy
Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics
Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?
Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).
Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).
Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study.
Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting.
Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study.
Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).
Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).
Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells
Improved survival of mesenchymal stem cells by macrophage migration inhibitory factor